RESEARCH AT TRL
Our pipeline, mainly focused on antibody-drug conjugates (ADCs), includes potential therapies that target specific molecules on cancer cells and modulate cancer cell function in ways that hold promise to improve human health.
Built by attaching a small molecule anticancer drug or another therapeutic agent to an antibody with a linker and, using the antibody's property to target a specific antigen only found on target cells, the ADCs deliver the highly potent drugs with a very high specificity to the cancer cells. They maximize the efficacy and minimize systemic exposure and their associated side effects.
Antibody Drug Conjugates – ADCs
TRL’s current programs utilize pyrrolobenzodiazepine (PBD)-based antibody drug conjugates (ADCs). TRL has multiple PBD-based ADCs in preclinical development and clinical trials.
Our lead program (MT-8633) is an anti-cMet ADC in a clinical trial for solid tumors. MT-8633 utilizes a humanized antibody specifically selected and engineered to be non-agonistic and efficiently deliver the toxic warhead to the DNA of tumor cells where it intercalates within the minor groove leading to disruption of replication, resulting in cell death.
CLINICAL STUDIES
MT-8633 (TR-1801-ADC) is an anti-cMet ADC comprising of a non-activating anti-Met antibody with a PBD toxin payload. It is currently in a Phase I dose escalation trial to evaluate safety, pharmacokinetics, and anti-tumor activity in patients with cMet+ solid tumors.
A CAREER WITH TANABE RESEARCH LABORATORIES
Interested in joining our team? We seek individuals who work with honesty and integrity; who are willing to push the boundaries and explore new ideas; who take ownership and thrive on accountability; and who perform their work with a sense of urgency, but also an optimistic and solution-oriented attitude.
